Format

Send to

Choose Destination
See comment in PubMed Commons below
Diabetes. 2012 Sep;61(9):2199-204. doi: 10.2337/db12-0052.

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Author information

  • 1Medicinal Chemistry, Amgen, Inc, South San Francisco, California, USA. jiwenl@amgen.com

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibition is a novel and promising treatment for diabetes under late-stage clinical development. It generally is accepted that SGLT2 mediates 90% of renal glucose reabsorption. However, SGLT2 inhibitors in clinical development inhibit only 30-50% of the filtered glucose load. Why are they unable to inhibit 90% of glucose reabsorption in humans? We will try to provide an explanation to this puzzle in this perspective analysis of the unique pharmacokinetic and pharmacodynamic profiles of SGLT2 inhibitors in clinical trials and examine possible mechanisms and molecular properties that may be responsible.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk